{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:05:28Z","timestamp":1792242328959,"version":"4.4.0"},"reference-count":35,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the current pharmacology, pharmacokinetics\/pharmacodynamics, safety, and efficacy of daridorexant in patients with insomnia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A literature search of PubMed (March 1, 2018, to October 19, 2022) and ClinicalTrials.gov search was conducted using the following terms: daridorexant and ACT-541468. Additional articles were identified by hand from references.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection and data extraction:<\/jats:title>\n                    <jats:p>We included English-language articles evaluating daridorexant pharmacology, efficacy, or safety in humans for the management of insomnia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data synthesis:<\/jats:title>\n                    <jats:p>Daridorexant has a peak plasma concentration of 1-2 hours, terminal half-life of 8 hours, and absolute bioavailability of 61%. Wake after sleep onset (WASO) significantly decreased from baseline to months 1 and 3 in daridorexant 25 (\u201318.40 and \u201322.97 min, P &lt; 0.0001) and 50 mg (\u201328.98 and \u201329.41 min, P &lt; 0.0001) groups compared with placebo. Latency to persistent sleep (LPS) significantly decreased from baseline to months 1 and 3 for daridorexant 25 mg (\u201328.17 and \u201330.73 min, P = 0.0005 and P = 0.0015) and 50 mg (\u201331.20 and \u201334.80 min, P &lt; 0.0001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to patient care and clinical practice in comparison to existing agents:<\/jats:title>\n                    <jats:p>Daridorexant can be administered in diverse patient populations because of its tolerability and favorable safety profile. However, due to the lack of large scale studies that directly compare dual orexin receptor antagonists (DORAs), there is not enough data to recommend 1 DORA over another.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Daridorexant is well tolerated and has demonstrated significant reductions in LPS and WASO in the treatment of insomnia in adult patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280221143794","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T05:40:51Z","timestamp":1672897251000},"page":"1076-1087","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Daridorexant: Comprehensive Review of A New Oral Agent for the Treatment of Insomnia"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8350-8392","authenticated-orcid":false,"given":"Juliane","family":"Park","sequence":"first","affiliation":[{"name":"SynerGrx, Chamblee, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kandon P.","family":"Render, PharmD","sequence":"additional","affiliation":[{"name":"SynerGrx, Chamblee, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew W.","family":"Cates, PharmD","sequence":"additional","affiliation":[{"name":"SynerGrx, Chamblee, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"key":"bibr1-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2021.04.002"},{"key":"bibr2-10600280221143794","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2020.42769"},{"key":"bibr3-10600280221143794","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.7172"},{"key":"bibr4-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-022-01357-w"},{"key":"bibr5-10600280221143794","doi-asserted-by":"publisher","DOI":"10.7326\/m15-2175"},{"key":"bibr6-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2020.1817380"},{"key":"bibr7-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-05954-0"},{"key":"bibr8-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25680"},{"key":"bibr9-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009475"},{"key":"bibr10-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13079"},{"key":"bibr11-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01028-8"},{"key":"bibr12-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01699-y"},{"key":"bibr13-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-021-01062-1"},{"key":"bibr14-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2592"},{"key":"bibr15-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119882854"},{"key":"bibr16-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsab224"},{"key":"bibr17-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa275"},{"key":"bibr18-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13248"},{"key":"bibr19-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-022-03381-4"},{"key":"bibr20-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-018-2559-5"},{"key":"bibr21-10600280221143794","unstructured":"US Food and Drug Administration. Daridorexant (Quviviq\u2122) for insomnia: integrated review template, version 2.0. Published 2022. Accessed 11 August 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/214985Orig1s000IntegratedR.pdf"},{"key":"bibr22-10600280221143794","unstructured":"Quviviq\u00ae (Daridorexant) [package insert]. Radnor PA; Idorsia Pharmaceuticals US Inc. 2022. Published January 2022. Accessed August 1, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214985s000lbl.pdf"},{"key":"bibr23-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15029"},{"key":"bibr24-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2021.05.005"},{"key":"bibr25-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00768-8"},{"key":"bibr26-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.13370"},{"key":"bibr27-10600280221143794","unstructured":"National Institutes of Health. Efficacy and safety of ACT-541468 in adult subjects with insomnia disorder. Published 2020. Accessed August 1, 2022. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02839200"},{"key":"bibr28-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00436-1"},{"key":"bibr29-10600280221143794","unstructured":"National Institutes of Health. Study to assess the efficacy and safety of ACT-541468 (daridorexant) in adult and elderly subjects suffering from difficulties to sleep. Published 2022. Accessed August 1, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03575104"},{"key":"bibr30-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-022-00977-4"},{"key":"bibr31-10600280221143794","unstructured":"Daridorexant. In: Lexi-Drugs. Lexi-Comp, Inc. Updated September 21, 2022. Accessed October 18, 2022. https:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/patch_f\/7189164"},{"key":"bibr32-10600280221143794","unstructured":"Zolpidem. In: Lexi-Drugs. Lexi-Comp, Inc. Updated October 19, 2022. Accessed October 19, 2022. https:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/patch_f\/7900"},{"key":"bibr33-10600280221143794","unstructured":"Temazepam. In: Lexi-Drugs. Lexi-Comp, Inc. Updated October 19, 2022. Accessed October 19, 2022. https:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/patch_f\/7731"},{"key":"bibr34-10600280221143794","unstructured":"Ramelteon. In: Lexi-Drugs. Lexi-Comp, Inc. Updated September 21, 2022. Accessed October 18, 2022. https:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/patch_f\/1500"},{"key":"bibr35-10600280221143794","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2021.101573"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221143794","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221143794","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221143794","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:12:58Z","timestamp":1777374778000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221143794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1177\/10600280221143794"],"URL":"https:\/\/doi.org\/10.1177\/10600280221143794","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,5]]}}}